P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma

International Journal of Gynecological Pathology

Volumn 16, Issue 1, 1997, Pages 69-75

  Khalifa, Mahmoud A ^a   Abdoh, Ahmed A ^b   Mannel, Robert S ^c   Walker, Joan L ^c   Angros, Lee H ^c   Min, Kyung Whan ^c  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Drug resistance; Gene expression; Ovarian neoplasms; P glycoprotein; Recurrent tumors

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030995629     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199701000-00011     Document Type: Article

References (26)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
2. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 1979;39: 2200-3.
3. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-8.
4. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance Nature 1986;324:485-9.
5. Hamada H, Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance: 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 1988;263:1454-8.
6. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58: 137-71.
7. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. JNCI 1989;81:116-24.
8. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-Glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990;21:34-48.
9. Katagiri A, Tomita Y, Nishiyama T, Kimura M, Sato S. Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. Br J Cancer 1993;68:125-9.
10. Grogan TM, Spier CM, Salmon SE, et al. P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-5.
11. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993;24:156-60.
12. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M. Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 1994;102:61-7.
13. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989;49:5062-5.
14. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. JNCI 1992; 84:1486-91.
15. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985;3:311-5.
16. Rubin SC, Finstad CL, Hoskins WJ, et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gvnecol 1990; 163:69-73.
17. FIGO Cancer Committee. Stage grouping for primary carcinoma of the ovary. Gynecol Oncol 1986;25:383-5.
18. Russell P. Surface epithelial-stromal tumors of the ovary. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 4th ed. New York: Springer-Verlag, 1994:705-82.
19. Scheper RJ, Bulte JWM, Brakkee JGP, et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 1988;42:389-94.
20. Grogan T, Dalton W, Rybski J, et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990;63:815-24.
21. Finstad CL, Yin BWT, Gordon CM, Federici MG, Welt S, Lloyd KO. Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis. J Histochem Cytochem 1991;39:1603-10.
22. Kaye SB. P glycoprotein (P-gp) and drug resistance - time for reappraisal. Br J Cancer 1993;67:641-3.
23. Weinstein R, Jakate SM, Dominguez JM, et al. Relationship of the expression of the mdr gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-6.
24. Bradley G, Sharma R, Rajalaskshmi S, Ling V. P-Glycoprotein expression during tumor progression in the rat liver. Cancer Res 1992;52:5154-61.
25. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
26. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-22.